1. Home
  2. NICM vs PYXS Comparison

NICM vs PYXS Comparison

Compare NICM & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nicola Mining Inc. American Depositary Shares

NICM

Nicola Mining Inc. American Depositary Shares

N/A

Current Price

$6.85

Market Cap

120.4M

Sector

N/A

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.08

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NICM
PYXS
Founded
N/A
2018
Country
Canada
United States
Employees
25
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
141.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NICM
PYXS
Price
$6.85
$3.08
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
3.2K
1.5M
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.32
$1.03
52 Week High
$6.78
$5.55

Technical Indicators

Market Signals
Indicator
NICM
PYXS
Relative Strength Index (RSI) 68.25 52.25
Support Level $5.92 $1.37
Resistance Level N/A $3.40
Average True Range (ATR) 0.33 0.46
MACD 0.10 -0.04
Stochastic Oscillator 97.24 56.43

Price Performance

Historical Comparison
NICM
PYXS

About NICM Nicola Mining Inc. American Depositary Shares

Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: